LinkedIn Profile

Access Asceneuron historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:asceneuron 2924417 Nov 18th, 2019 12:00AM Asceneuron SA 751 16.00 Open Biotechnology Nov 18th, 2019 03:45PM Nov 18th, 2019 03:45PM Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.com Open Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology Open EPFL Innovation Park, Bâtiment B Lausanne Vaud CH CH-1015 Health Care Health Care Equipment & Services
private:asceneuron 2924417 Nov 16th, 2019 12:00AM Asceneuron SA 751 16.00 Open Biotechnology Nov 16th, 2019 03:56PM Nov 16th, 2019 03:56PM Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.com Open Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology Open EPFL Innovation Park, Bâtiment B Lausanne Vaud CH CH-1015 Health Care Health Care Equipment & Services
private:asceneuron 2924417 Nov 15th, 2019 12:00AM Asceneuron SA 750 16.00 Open Biotechnology Nov 15th, 2019 12:38PM Nov 15th, 2019 12:38PM Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.com Open Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology Open EPFL Innovation Park, Bâtiment B Lausanne Vaud CH CH-1015 Health Care Health Care Equipment & Services
private:asceneuron 2924417 Nov 14th, 2019 12:00AM Asceneuron SA 750 16.00 Open Biotechnology Nov 14th, 2019 05:54PM Nov 14th, 2019 05:54PM Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.com Open Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology Open EPFL Innovation Park, Bâtiment B Lausanne Vaud CH CH-1015 Health Care Health Care Equipment & Services
private:asceneuron 2924417 Nov 13th, 2019 12:00AM Asceneuron SA 748 16.00 Open Biotechnology Nov 13th, 2019 01:06PM Nov 13th, 2019 01:06PM Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.com Open Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology Open EPFL Innovation Park, Bâtiment B Lausanne Vaud CH CH-1015 Health Care Health Care Equipment & Services
private:asceneuron 2924417 Nov 12th, 2019 12:00AM Asceneuron SA 748 16.00 Open Biotechnology Nov 12th, 2019 02:48PM Nov 12th, 2019 02:48PM Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.com Open Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology Open EPFL Innovation Park, Bâtiment B Lausanne Vaud CH CH-1015 Health Care Health Care Equipment & Services
private:asceneuron 2924417 Nov 11th, 2019 12:00AM Asceneuron SA 747 16.00 Open Biotechnology Nov 11th, 2019 02:46PM Nov 11th, 2019 02:46PM Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.com Open Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology Open EPFL Innovation Park, Bâtiment B Lausanne Vaud CH CH-1015 Health Care Health Care Equipment & Services
private:asceneuron 2924417 Nov 10th, 2019 12:00AM Asceneuron SA 746 16.00 Open Biotechnology Nov 10th, 2019 05:52PM Nov 10th, 2019 05:52PM Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.com Open Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology Open EPFL Innovation Park, Bâtiment B Lausanne Vaud CH CH-1015 Health Care Health Care Equipment & Services
private:asceneuron 2924417 Nov 9th, 2019 12:00AM Asceneuron SA 746 16.00 Open Biotechnology Nov 9th, 2019 05:20PM Nov 9th, 2019 05:20PM Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.com Open Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology Open EPFL Innovation Park, Bâtiment B Lausanne Vaud CH CH-1015 Health Care Health Care Equipment & Services
private:asceneuron 2924417 Nov 8th, 2019 12:00AM Asceneuron SA 745 16.00 Open Biotechnology Nov 8th, 2019 02:30PM Nov 8th, 2019 02:30PM Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.com Open Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology Open EPFL Innovation Park, Bâtiment B Lausanne Vaud CH CH-1015 Health Care Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.